Search Results - "Woo, V. C."

One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial by Gough, S. C. L., Bode, B. W., Woo, V. C., Rodbard, H. W., Linjawi, S., Zacho, M., Reiter, P. D., Buse, J. B.

“…Aims To confirm, in a 26‐week extension study, the sustained efficacy and safety of a fixed combination of insulin degludec and liraglutide (IDegLira) compared…”
Get full text

Excimer laser photorefractive keratectomy for myopia: six-month follow-up by Tong, P P, Kam, J T, Lam, R H, Leung, W K, Woo, V C, Chow, P C, Hung, S O, Wong, W F, Wong, T W

“…In this study, 108 eyes of 62 patients had photorefractive keratectomy (PRK) with a 193 nm excimer laser to correct myopia. The eyes were assigned to one of…”
Get more information

Greater Combined Reductions of HbA1c ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators by Dungan, Kathleen M., Bardtrum, Lars, Christiansen, Erik, Eliasson, Johanna, Mellbin, Linda, Woo, Vincent C., Vilsbøll, Tina

“…Introduction A post hoc analysis of the PIONEER 1–5 and 8 trials assessed the clinically relevant composite endpoints of HbA 1c (glycated haemoglobin)…”
Get full text

Greater Combined Reductions of HbA 1c  ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators by Dungan, Kathleen M, Bardtrum, Lars, Christiansen, Erik, Eliasson, Johanna, Mellbin, Linda, Woo, Vincent C, Vilsbøll, Tina

“…A post hoc analysis of the PIONEER 1-5 and 8 trials assessed the clinically relevant composite endpoints of HbA (glycated haemoglobin) reduction ≥ 1% and body…”
Get full text

Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin by Yu, Huan, Woo, Vincent C

“…The aim of this article is to review the safety and efficacy data of dapagliflozin, saxagliptin, and their combination in the management of patients with type…”
Get full text

Glycaemic and body weight responses to oral semaglutide in the PIONEER trial programme by Mellbin, L, Christiansen, E, Hertz, CL, Nielsen, MA, Vilsboll, T, Woo, VC, Dungan, KM

Get full text

Bacteremic pneumonia caused by penicillin-resistant pneumococci: Case report and review with a Canadian perspective by Burdge, D R, Woo, V C, Ritchie, P M

“…A Canadian adult with bacteremic pneumonia caused by a relatively penicillin-resistant (minimal inhibitory concentration 0.25 μg/mL) Streptococcus pneumoniae…”
Get full text

Bacteremic pneumonia caused by penicillin-resistant pneumococci: Case report and review with a Canadian perspective by Burdge, D R, Woo, V C, Ritchie, P M

Get full text